Phase 2 trial of neoadjuvant chemotherapy and transoral endoscopic surgery with risk-adapted adjuvant therapy for squamous cell carcinoma of the head and neck

Palbociclib and cetuximab compared with placebo and cetuximab in platinum-resistant, cetuximab-naïve, human papillomavirus-unrelated recurrent or metastatic head and neck squamous cell carcinoma: A double-blind, randomized, phase 2 trial

Oral Oncology ◽

10.1016/j.oraloncology.2021.105192 ◽

2021 ◽

Vol 115 ◽

pp. 105192

Author(s):

Douglas R. Adkins ◽

Jin-Ching Lin ◽

Assuntina Sacco ◽

Jessica Ley ◽

Peter Oppelt ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Human Papillomavirus ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Double Blind ◽

Phase 2 Trial ◽

Randomized Phase 2

Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(21)00136-4 ◽

2021 ◽

Author(s):

Assuntina G Sacco ◽

Ruifeng Chen ◽

Francis P Worden ◽

Deborah J L Wong ◽

Douglas Adkins ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Open Label ◽

Multicentre Phase ◽

Phase 2 Trial of Continuous Course Re-irradiation Concurrent With Weekly Cisplatinum and Cetuximab for Recurrent Squamous Cell Carcinoma of the Head and Neck: Preliminary Report

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2014.05.697 ◽

2014 ◽

Vol 90 (1) ◽

pp. S179

Author(s):

M. Yao ◽

D. Wang ◽

B.D. Sumer ◽

M. Larry ◽

J. Truelson ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Preliminary Report ◽

Phase 2 ◽

Phase 2 Trial ◽

Recurrent Squamous Cell Carcinoma

A Prospective Phase 2 Trial of Reirradiation With Stereotactic Body Radiation Therapy Plus Cetuximab in Patients With Previously Irradiated Recurrent Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2014.11.023 ◽

2015 ◽

Vol 91 (3) ◽

pp. 480-488 ◽

Cited By ~ 74

Author(s):

John A. Vargo ◽

Robert L. Ferris ◽

James Ohr ◽

David A. Clump ◽

Kara S. Davis ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Radiation Therapy ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Stereotactic Body Radiation Therapy ◽

Phase 2 ◽

Phase 2 Trial ◽

Recurrent Squamous Cell Carcinoma ◽

Prospective Phase

Phase 2 Trial of Adjuvant Concurrent Cetuximab and Radiation for High-Risk Cutaneous Squamous Cell Carcinoma of the Head and Neck

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.12.050 ◽

2018 ◽

Vol 100 (5) ◽

pp. 1324

Author(s):

M. Mierzwa ◽

K. Casper ◽

K.P. Redmond ◽

W.L. Barrett ◽

V. Takiar ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

High Risk ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Cutaneous Squamous Cell Carcinoma ◽

Phase 2 ◽

A phase 2 trial of inductionnab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck

Cancer ◽

10.1002/cncr.27741 ◽

2012 ◽

Vol 119 (4) ◽

pp. 766-773 ◽

Cited By ~ 18

Author(s):

Douglas Adkins ◽

Jessica Ley ◽

Kathryn Trinkaus ◽

Wade Thorstad ◽

James Lewis ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Advanced Squamous Cell Carcinoma ◽

Phase 2 ◽

Randomized phase 2 trial of patritumab (P) or placebo (PBO) + cetuximab (C) + cisplatin (CIS) or carboplatin (CAR) for recurrent and/or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.6045 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 6045-6045 ◽

Cited By ~ 6

Author(s):

Kevin J. Harrington ◽

Martin David Forster ◽

Christophe Le Tourneau ◽

Jose Ariza ◽

Shuquan Chen ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

Randomized Phase 2

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

The Lancet Oncology ◽

10.1016/s1470-2045(20)30755-5 ◽

2021 ◽

Vol 22 (4) ◽

pp. 463-475

Author(s):

Joël Guigay ◽

Anne Aupérin ◽

Jérôme Fayette ◽

Esma Saada-Bouzid ◽

Cédrik Lafond ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Open Label ◽

Phase 2 Trial ◽

First Line Treatment

Phase 2 Trial of AT-101 in Combination With Docetaxel for Recurrent, Locally Advanced, or Metastatic Head-and-Neck Squamous Cell Carcinoma (HNSCC)

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2013.11.140 ◽

2014 ◽

Vol 88 (2) ◽

pp. 507 ◽

Cited By ~ 1

Author(s):

A. Sacco ◽

J. Nor ◽

E. Belile ◽

A. Sukari ◽

D. Chepeha ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Locally Advanced ◽

Phase 2 ◽

Intralesional SD-101 in combination with pembrolizumab in anti-PD-1 treatment naive head and neck squamous cell carcinoma: results from a multicenter, phase 2 trial

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-21-1411 ◽

2021 ◽

pp. clincanres.1411.2021

Author(s):

Ezra E.W. Cohen ◽

Lisle Nabell ◽

Deborah J. Wong ◽

Terry Day ◽

Gregory A. Daniels ◽

...

Keyword(s):

Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Head And Neck ◽

Squamous Cell ◽

Phase 2 ◽

Phase 2 Trial ◽

Multicenter Phase ◽

Treatment Naïve